T01

To exploit the therapeutic potential of PI3K inhibition during the hemolytic-uremic syndrome (HUS), a compartmentalized delivery strategy of kinase-inhibitors (such as AS605240) to the kidney seems promising to allow avoiding off-target effects, e. g. on systemic immune functionality. We aim to design functionalized nanoparticles that rely on modification of polymers with dyes that may act as targeting ligands for organic anion transporters that confer compartmentalized delivery to the kidney. In vitro effects of the dye-tagged particles loaded with the inhibitor AS605240 will be examined in human microvascular endothelial cells under physiological and pathophysiological conditions to detect mechanisms and key features conferring cell damage and prevention. The in vivo performance of the biocompatible nanoformulated PI3K inhibitors will be evaluated with respect to their enrichment and compartmentalization in the kidneys applying comprehensive biophotonic strategies.